Bharat Biotech Unveils Oral Vaccine to Tackle Global Cholera Threat

On Tuesday, Bharat Biotech introduced an oral cholera vaccine aimed at combating the persistent global threat of cholera, particularly in areas with poor sanitation.

Bharat Biotech announced the release of an oral cholera vaccine (OCV), a significant public health issue in regions with inadequate sanitation ().

HILLCHOL (BBV131), a novel single-strain vaccine is to be administered orally on day 0 and day 14. It is suitable for babies older than one year.

Cholera
Cholera is an infection of the small intestine and is caused by the bacterium Vibrio cholerae.

‘ Did You Know?
With proper treatment, the mortality rate for cholera can be reduced to less than 1%, highlighting the importance of timely medical intervention. #cholera #choleravaccine ’

In a statement, Bharat Biotech said the vaccine was developed under license from Singapore-based Hilleman Laboratories, and added that large-scale manufacturing facilities have been established in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses.

“Vaccines provide the best intervention to prevent, limit, and control cholera outbreaks Our new large-scale cGMP production facilities in Hyderabad and Bhubaneswar will significantly enhance our production and supply capabilities for this Oral Cholera Vaccine, advancing our efforts to combat cholera globally,” said Dr. Krishna Ella, Executive Chairman of Bharat Biotech.

Oral Cholera Vaccine Introduced

While cholera is preventable and treatable, global cases and deaths have risen steadily since 2021. From early 2023 to March this year, 824,479 cases and 5,900 deaths were reported in 31 countries.

UN Intensifies Efforts Against Cholera in Somalia Amid Rising Death Toll
The United Nations humanitarian agency has heightened its response to tackle the cholera outbreak in Somalia, with the death toll reaching 120 since January.

While global demand for OCVs exceeds 100 million doses annually, there is currently only one manufacturer supplying OCVs worldwide, resulting in a yearly deficit of about 40 million doses.

The new vaccine will bridge the gap and also contribute substantially to the Global Task Force on Cholera Control (GTFCC)'s goal of reducing cholera-related deaths by 90 percent by 2030, alongside improvements in water and sanitation infrastructure.

Cholera Oral Vaccine: WHO Prequalifies a New Simplified Vaccine
The World Health Organization (WHO) has prequalified a new oral cholera vaccine, a simplified formulation that will help increase its production capacity.

Notably, HILLCHOL's safety and efficacy have been established by pre-clinical, Phase I, II, and III clinical studies, the company said.

“A multi-stage clinical evaluation process, culminating in a Phase III study, confirmed the vaccine's safety, immunogenicity, and non-inferiority to existing OCVs, establishing its potential for widespread public health use,” it added.

Urgent Action Needed to Combat Cholera Crisis on World Water Day
Millions face cholera due to water scarcity & vaccine shortage. Urgent action needed.

HILLCHOL vaccine is presented as a single-dose respule and should be stored between +2 degrees Celsius and +8 degrees Celsius. It is also presented in a mono-multidose format, one of the first such presentations for vaccines.

Reference:

Unique International Collaboration Brings Breakthrough Oral Cholera Vaccine to Market - 0028https://hilleman-labs.org/press-release/unique-international-collaboration-brings-breakthrough-oral-cholera-vaccine-to-market/)

Source-IANS